Aquestive Therapeutics, Inc. (AQST) stock
AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.70−0.06 (-1.60%)
Close on Nov 17, 2026Market cap $464.39MP/E –Yield –
Aquestive Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Aquestive Therapeutics's price to sales ratio was 8.3× on Nov 11, 2026, against 17.4× a year earlier. Over the last 5 years it ranged from 0.5× to 18.1×, with a median of 4.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 8.3× | −9.8 |
| 2025 | Dec 31, 2025 | 18.1× | +12.6 |
| 2024 | Dec 31, 2024 | 5.5× | +2.7 |
| 2023 | Dec 29, 2023 | 2.8× | +1.8 |
| 2022 | Dec 30, 2022 | 1.0× | −2.3 |
| 2021 | Dec 31, 2021 | 3.3× | +0.1 |
| 2020 | Dec 31, 2020 | 3.3× | +0.5 |
| 2019 | Dec 31, 2019 | 2.7× | +0.6 |
| 2018 | Dec 31, 2018 | 2.1× | – |
See a number that looks wrong?